Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel (5 mg/g Brimonidine Tartrate) in Patients With Chronic Persistent Vascular Facial Erythema.

NCT02856919 is registered in ClinicalTrials.gov with Galderma Brasil Ltda. as lead sponsor.

NCT NCT02856919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02856919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel (5 mg/g Brimonidine Tartrate) in Patients With Chronic Persistent Vascular Facial Erythema.
Lead sponsor
Galderma Brasil Ltda.
Phase
Phase 4
Overall status
Completed
Start date
June 13, 2016
Completion date
February 8, 2017
Enrollment
101 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic persistent vascular facial erythema